ArticleTranslational lung cancer research2021
Isochorismatase domain-containing protein 1 (ISOC1) participates in DNA damage repair and inflammation-related pathways to promote lung cancer development.
Article in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Exploring potential biomarkers of diffuse large B-cell lymphoma through multi-dimensional data.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- A brief history of the human liver peroxisome.Histochemistry and cell biology · 2026Review
- Defining the cell and molecular origins of the primate ovarian reserve.Nature communications · 2025Article
- Integrative Analysis of GEO Datasets and Mendelian Randomization Reveals a Potential Role ofISOC1 in Renal Cell Carcinoma.Journal of Cancer · 2025Article
- Identification of Plasma Protein Biomarkers and Drug Targets for Hematologic Malignancies by Proteome-wide Mendelian Randomization.Journal of Cancer · 2025Article
- Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Selpercatinib and capmatinib combination promotes sustained complete response in novelFrontiers in oncology · 2023Article
- Ten Years of CRISPRing Cancers In Vitro.Cancers · 2022Review
- ISOC1 Modulates Inflammatory Responses in Macrophages through the AKT1/PEX11B/Peroxisome Pathway.Molecules (Basel, Switzerland) · 2022Article
- Analysis of Secreted Proteins from Prepubertal Ovarian Tissues Exposed In Vitro to Cisplatin and LH.Cells · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe advent of novel molecular targets has dramatically changed the treatment landscape of lung cancer in recent years. Isochorismatase domain-containing protein 1 (
methodsThe expression levels and prognostic significance of
resultsOur results found that
conclusionsWe demonstrated that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.